Trial Search Results

Study of SGN-40 in Patients With Relapsed Diffuse Large B-Cell Lymphoma

This is a Phase II, open-label, multidose trial of SGN-40 designed to estimate objective response rate and assess toxicity in patients with relapsed DLBCL.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Seagen Inc.

Collaborator: Genentech, Inc.

Stanford Investigator(s):

Intervention(s):

  • Drug: SGN-40

Phase:

Phase 2

Eligibility


Inclusion Criteria:

   - Diagnosis of DLBCL.

   - Received at least one combination chemotherapy regimen with rituximab, such as R-CHOP,
   R-ESHAP or equivalent.

   - Progression or relapse since most recent therapy.

   - At least one measurable lesion that is both greater than or equal to 2 cm by
   conventional CT or greater than or equal to 1.5 cm by spiral CT.

Exclusion Criteria:

   - Previous diagnosis or treatment for indolent lymphoma, leptomeningeal lymphoma, or
   central nervous system lymphoma.

   - Primary refractory disease.

   - Received an allogenic stem cell transplant.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Ranjana Advani
6507248372
Not Recruiting